ClinicalTrials.gg
Status unknownNCT04317833Updated Mar 23, 2020

A Study of SSS17 in Healthy Subjects

A Phase 1 interventional study of SSS17 and Placebo in Anemia in Chronic Kidney Diseases, sponsored by Shenyang Sunshine Pharmaceutical Co., LTD.. Status unknown at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-23.

Sponsored by Shenyang Sunshine Pharmaceutical Co., LTD. (part of 3SBio Inc.) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 115 studies in Anemia with a site in China — 33 open to participants now, 42 under way, 8 of them phase 3. Anemia · China.

Planned enrollment
69th of 97
65 · median 120
Started
2020
with 7 others
Phase 1
9 of 115
3 open now
Registered
42nd of 115
by date
Lead sponsor
4 of 115
Shenyang Sunshine Pharmaceutical Co., LTD.

Among the 115 studies in Anemia with a site in China, this one is the 69th largest by planned enrollment of the 97 interventional ones that give a count, is one of 8 that started in 2020, is one of 9 in phase 1, and was the 42nd registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

33 of the 115 studies in Anemia with a site in China are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Anemia with a site in China, or all of them as a file.
02

Study summary

This is a first-in-human, Phase 1, single-center, randomized, single-blind, placebo-controlled, single dose-escalation study to evaluate the safety, tolerability, PK, PD of SSS17 following oral administration in healthy subjects. Approximately 65 subjects (53 receiving active drug and 12 receiving placebo) will participate in this study.

Read the detailed description

The study will enroll healthy volunteers from a single academic medical center in China. All participants will be informed about the study and potential risks and required to provide written informed consent prior to undergoing study-related procedures.

The improved Fibonacci dose escalation design will be implemented. The protocol specifies 10 mg, oral, one time for the first cohort without placebo control. Successive cohorts will be given doses up to 540 mg with placebo parallel control. Only no observation meets the criteria under stop rules, dose will escalate to the next higher level.

The study will be divided into 2 stages: 1st period (fast) and 2nd period(fed).

First period (fast): Subjects will be allocated 1:4 to receive placebo or SSS17, which will be administered by oral route. At each dose, tolerability, safety, PK and PD characteristics will be investigated.

Second period (fed): in order to investigate the effects of food on PK and PD of SSS17. Subjects in one cohort will be administered again after meal on Day15. The accurate dose will be adjusted according to the findings in 1st period (fast)

03

Conditions studied

  • Anemia in Chronic Kidney Diseases

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight≥50 for male or ≥45 for female, and between 19.0-26.0 kg/m2
  • Good general health as determined by the investigator based on medical history, physical examination, vital signs, 12-lead , clinical laboratory tests and B-type ultrasound test.
  • Participants of must agree to utilize reliable methods of from screening to 6 months after the last administration of the study intervention. No plan for sperm (or egg) donation or pregnancy.
  • Understand and sign the .
  • Ability to understand and follow study-related instruction

Exclusion criteria

Exclusion Criteria:

  • A known allergy to any component of the SSS17 formulation, or allergy history of two kinds of drugs or food
  • Medical history or conditions of digestive system.
  • Female volunteers who are pregnant, menstrual, lactating or menopause with hormone therapy.
  • Eyes diseases, including diabetic retinopathy, age-related macular degeneration.
  • Vascular anomalies.
  • Drug, alcohol or nicotine addiction.
  • Blood donation or bleeding (more than 200 ml). Experience of treatment with EPO or blood transfusion.
  • Any findings from the medical examination (including medical history, physical examination, vital signs, laboratory tests and ) deviating from normal and deemed by the investigator to be of clinical relevance
  • Abnormal results in test of TIBC, serum iron or ferritin
  • Acute diseases before administration.
  • Other situations that the researcher believes may affect validity judgment or are not suitable for participation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
65 participants (estimated)

Study arms

  • Experimental
    Dose Escalation SSS17

    Escalating doses of SSS17; single dose administration; different dosage forms (redosing of the SSS17 in one cohort with food on Day15)

    Drug: SSS17

  • Placebo comparator
    Escalation matching Placebo

    Escalating doses of matching placebo; single dose administration; different dosage forms (redosing of matching placebo in one cohort with food on Day15)

    Drug: Placebo

Interventions

  • DrugSSS17

    SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxia-inducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.

  • DrugPlacebo

    matched placebo

06

What researchers measure

Primary outcomes

  1. AEs

    assessment AEs by frequency, severity

    Time frame: up to Day14 or 29

Secondary outcomes

  1. Maximum plasma concentration (Cmax) of SSS17

    Plasma samples will be collected and Cmax will be assessed.

    Time frame: [ up to 48 hours post-dose]

  2. Area under the concentration-time curve (AUC) of plasma concentration of SSS17

    Plasma samples will be collected and the AUC from zero to infinity will be assessed.

    Time frame: [ up to 48 hours post-dose]

  3. Time-to-Cmax (Tmax) of SSS 17

    Plasma samples will be collected and the Tmax will be assessed from the concentration-time curve.

    Time frame: [ up to 48 hours post-dose]

  4. Elimination terminal half-life (t1/2) of SSS17

    Plasma samples will be collected and the t1/2 will be assessed.

    Time frame: [up to 48 hours post-dose]

  5. Total amount of SSS17 excreted in urine over 24 hours (Ae0-24)

    Urine sample will be collected at pre-specified intervals and Ae0-24 will be assessed.

    Time frame: only for one cohort (up to 72 hours post-dose)

  6. Fraction of SSS17 excretion during each collection interval (Fe0-24)

    Urine sample will be collected at pre-specified intervals and Fe0-24 will be assessed.

    Time frame: only for one cohort (up to 72 hours post-dose)

  7. Total amount of SSS17 excreted in urine over 72 hours (Ae0-72)

    Urine sample will be collected at pre-specified intervals and Ae0-72 will be assessed.

    Time frame: only for one cohort (up to 72 hours post-dose)

  8. Fraction of SSS17 excretion during each collection interval (Fe0-72)

    Urine sample will be collected at pre-specified intervals and Fe0-72 will be assessed.

    Time frame: only for one cohort (up to 72 hours post-dose)

  9. Renal clearance (CLR) of SSS17

    Urine sample will be collected at pre-specified intervals and CLR will be assessed.

    Time frame: only for one cohort (up to 72 hours post-dose)

  10. EPO concentrations

    Change of EPO concentrations from baseline following SSS17

    Time frame: up to 168 hours post-dose.

  11. VEGF concentrations

    Change of VEGF concentrations from baseline following SSS17

    Time frame: up to 168 hours post-dose.

  12. Change of RTC from baseline

    Change of RTC from baseline following SSS17

    Time frame: up to 168 hours post-dose.

  13. Change of RBC from baseline

    Change of RBC from baseline following SSS17

    Time frame: up to 168 hours post-dose.

  14. Change of Hgb from baseline

    Change of Hgb from baseline following SSS17

    Time frame: up to 168 hours post-dose.

  15. Change of hepcidin from baseline

    Change of serum hepcidin concentrations from baseline following SSS17

    Time frame: up to 168 hours post-dose.

07

Study locations

1 site
  • Shanghai Public Health Clinical Center
    Shanghai, Shanghai 201203, China
    • Hongzhou Lu · Contact
    • Hongzhou Lu · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2020; primary completion for Jun 2021, 13 months later.

Of 34 industry-sponsored phase 1 interventional studies under Anemia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 30. This study's planned 13 months is above that.

Counting every sponsor, half of 48 studies reached it within 12 months; a quarter within 3 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2020
First posted
Mar 23, 2020
StartEst.
May 1, 2020
Primary completionEst.
Jun 30, 2021
CompletionEst.
Dec 31, 2021
Last update
Mar 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04317833
Responsible party
Sponsor
First posted
Mar 23, 2020
Start date
May 1, 2020 (estimated)
Primary completion
Jun 30, 2021 (estimated)
Completion
Dec 31, 2021 (estimated)
Last update
Mar 23, 2020

Study contacts

Hongzhou Lu, Ph.D
Contact
jigouban@126.com
(021)37990333-5278

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SSS17

Start the discussion